FDA Approves New Oral Weight-Loss Pill
California News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
FDA Approves Eli Lillys Orforglipron for Weight Loss: A New Oral Option for Obesity Treatment
The FDA has greenlit Eli Lillys new weight-loss pill, Orforglipron (Foundayo), marking the second daily oral option for obesity and related issues. This GLP-one drug, which mimics a natural hormone to reduce appetite and increase fullness, will be available starting Monday. Prices range from $149 to $349 per month, with a potential $25 monthly cost via Lillys discount card. Foundayo stands out for its simplicity, as it can be taken at any time, unlike Novo Nordisks Wegovy, which requires an empty stomach and a 30-minute wait before eating. Clinical trial participants saw improvements in waist size, blood pressure, triglycerides, and cholesterol levels, with gastrointestinal side effects causing around 5-10% of users to discontinue treatment. The approval comes under a new FDA program, with Lillys stock climbing over 4% on the news. This development aligns with the Trump administrations efforts to lower GLP-one drug prices, making obesity treatment more accessible.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/6db88918aa3d3f64